5-fluorouracil

This study examined the effects of five anticancer agents-cisplatin, 5-fluorouracil, vincristine, irinotecan, and cyclophosphamide-on mouse skeletal muscle. Targeting ER stress may help prevent chemotherapy-induced muscle wasting. Further studies are needed to clarify mechanisms and develop protective strategies.

Among these, compound 10 h demonstrated the most potent antiproliferative effect (IC50 = 4.05 ± 0.67 μM), significantly outperforming the reference drug 5-fluorouracil (IC50 = 17.43 ± 4.66 μM), while exhibiting minimal toxicity toward normal liver L02 cells (IC50 > 40 μM). In vivo, 10 h significantly suppressed tumor growth in a HepG2 xenograft model without overt toxicity. Collectively, these findings establish 10 h as a highly potent and selective anticancer lead compound, acting via DNA damage-induced S-phase arrest and mitochondrial-mediated apoptosis, and highlight its potential for further development as a liver cancer therapeutic.

P3, N=390, Not yet recruiting, Tang-Du Hospital | Initiation date: May 2025 --> Feb 2026

In post-hoc analyses, median progression-free survival was 26 months (95% CI: 14.7-34.3), and median overall survival was 38 months (95% CI: 27.9-not reached). Exploratory gene expression, immunohistochemistry and spatial transcriptomics showed increased intratumoral plasma cells and CD8 T cells in treated patients versus mFFX-only controls, and lymphoid aggregates with high plasma-cell-to-B cell ratios enriched for terminally exhausted CD8 T cells with fewer progenitor exhausted CD8 T cells and central memory CD4 T cells.

In the NEN cell lines BON-1, QGP-1, and MS-18, we applied cisplatin, etoposide, streptozotocin, 5-fluorouracil, temozolomide, and everolimus- all systemic agents used in highly proliferative NEN. These findings might have an impact on the optimal therapy sequence and patient selection for future CXCR4-targeted approaches. Further, the decreased CXCR4 expression could represent a new mechanism of action of the established drugs Cisplatin, Temozolomide, and Everolimus.

P=N/A, N=34, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital

P=N/A, N=444, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o

P=N/A, N=150, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital

P=N/A, N=29, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital

P=N/A, N=40, Not yet recruiting, Chizhou People's Hospital; Chizhou People's Hospital

P=N/A, N=12, Not yet recruiting, Fujian Cancer Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.

P4, N=102, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University